Literature DB >> 25605817

Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?

Vijay Ramaswamy1, Marc Remke1, Jennifer Adamski1, Ute Bartels1, Uri Tabori1, Xin Wang1, Annie Huang1, Cynthia Hawkins1, Donald Mabbott1, Normand Laperriere1, Michael D Taylor1, Eric Bouffet1.   

Abstract

BACKGROUND: The advent of integrated genomics has fundamentally changed our understanding of medulloblastoma. Although survival differences exist among the 4 principal subgroups, this has yet to be elucidated in a North American cohort of irradiated patients.
METHODS: Ninety-two consecutive patients between the ages of 3 and 17 treated with surgery, craniospinal irradiation, and chemotherapy were identified at the Hospital for Sick Children. Molecular subgrouping was performed using nanoString.
RESULTS: Two treatment periods were identified: prior to 2006 as per the protocols of the Children's Oncology Group, and after 2006 per the St Jude Medulloblastoma 03 protocol. Five-year progression-free survival (PFS) over the entire cohort was 0.801 (95% CI: 0.692-0.875) with no significant difference between treatment protocols. Strikingly, we found that Group 4 patients had excellent 5-year PFS of 0.959 (95% CI: 0.744-0.994) for average risk and 0.887 (95% CI: 0.727-0.956) across all Group 4 patients. Group 3 patients had 5-year PFS of 0.733 (95% CI: 0.436-0.891). Sonic hedgehog patients did poorly across both treatment protocols, with 5-year PFS of 0.613 (95% CI: 0.333-0.804), likely owing to a high proportion of TP53 mutated patients in this age group.
CONCLUSIONS: In a cohort of irradiated patients over 3 years of age, PFS for Group 4 patients was significantly improved compared with initial reports. The impact of subgroup affiliation in these children needs to be assessed in large prospectively treated cooperative protocols to determine if more than just WNT patients can be safely selected for de-escalation of therapy.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chemotherapy; medulloblastoma; radiation; subgroups

Mesh:

Year:  2015        PMID: 25605817      PMCID: PMC4724171          DOI: 10.1093/neuonc/nou357

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  22 in total

1.  Adult medulloblastoma comprises three major molecular variants.

Authors:  Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

3.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Authors:  Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

4.  Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.

Authors:  Uri Tabori; Berivan Baskin; Mary Shago; Noa Alon; Michael D Taylor; Peter N Ray; Eric Bouffet; David Malkin; Cynthia Hawkins
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

5.  FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

Authors:  Marc Remke; Thomas Hielscher; Andrey Korshunov; Paul A Northcott; Sebastian Bender; Marcel Kool; Frank Westermann; Axel Benner; Huriye Cin; Marina Ryzhova; Dominik Sturm; Hendrik Witt; Daniel Haag; Grischa Toedt; Andrea Wittmann; Anna Schöttler; André O von Bueren; Andreas von Deimling; Stefan Rutkowski; Wolfram Scheurlen; Andreas E Kulozik; Michael D Taylor; Peter Lichter; Stefan M Pfister
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

6.  Medulloblastoma comprises four distinct molecular variants.

Authors:  Paul A Northcott; Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Charles G Eberhart; Stephen Mack; Eric Bouffet; Steven C Clifford; Cynthia E Hawkins; Pim French; James T Rutka; Stefan Pfister; Michael D Taylor
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

7.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

Authors:  Marcel Kool; David T W Jones; Natalie Jäger; Paul A Northcott; Trevor J Pugh; Volker Hovestadt; Rosario M Piro; L Adriana Esparza; Shirley L Markant; Marc Remke; Till Milde; Franck Bourdeaut; Marina Ryzhova; Dominik Sturm; Elke Pfaff; Sebastian Stark; Sonja Hutter; Huriye Seker-Cin; Pascal Johann; Sebastian Bender; Christin Schmidt; Tobias Rausch; David Shih; Jüri Reimand; Laura Sieber; Andrea Wittmann; Linda Linke; Hendrik Witt; Ursula D Weber; Marc Zapatka; Rainer König; Rameen Beroukhim; Guillaume Bergthold; Peter van Sluis; Richard Volckmann; Jan Koster; Rogier Versteeg; Sabine Schmidt; Stephan Wolf; Chris Lawerenz; Cynthia C Bartholomae; Christof von Kalle; Andreas Unterberg; Christel Herold-Mende; Silvia Hofer; Andreas E Kulozik; Andreas von Deimling; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Martin Hasselblatt; John R Crawford; Gerald A Grant; Nada Jabado; Arie Perry; Cynthia Cowdrey; Sydney Croul; Gelareh Zadeh; Jan O Korbel; Francois Doz; Olivier Delattre; Gary D Bader; Martin G McCabe; V Peter Collins; Mark W Kieran; Yoon-Jae Cho; Scott L Pomeroy; Olaf Witt; Benedikt Brors; Michael D Taylor; Ulrich Schüller; Andrey Korshunov; Roland Eils; Robert J Wechsler-Reya; Peter Lichter; Stefan M Pfister
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

8.  Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.

Authors:  Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

9.  Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.

Authors:  Torsten Pietsch; Rene Schmidt; Marc Remke; Andrey Korshunov; Volker Hovestadt; David T W Jones; Jörg Felsberg; Kerstin Kaulich; Tobias Goschzik; Marcel Kool; Paul A Northcott; Katja von Hoff; André O von Bueren; Carsten Friedrich; Martin Mynarek; Heyko Skladny; Gudrun Fleischhack; Michael D Taylor; Friedrich Cremer; Peter Lichter; Andreas Faldum; Guido Reifenberger; Stefan Rutkowski; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2014-05-04       Impact factor: 17.088

10.  Cytogenetic prognostication within medulloblastoma subgroups.

Authors:  David J H Shih; Paul A Northcott; Marc Remke; Andrey Korshunov; Vijay Ramaswamy; Marcel Kool; Betty Luu; Yuan Yao; Xin Wang; Adrian M Dubuc; Livia Garzia; John Peacock; Stephen C Mack; Xiaochong Wu; Adi Rolider; A Sorana Morrissy; Florence M G Cavalli; David T W Jones; Karel Zitterbart; Claudia C Faria; Ulrich Schüller; Leos Kren; Toshihiro Kumabe; Teiji Tominaga; Young Shin Ra; Miklós Garami; Peter Hauser; Jennifer A Chan; Shenandoah Robinson; László Bognár; Almos Klekner; Ali G Saad; Linda M Liau; Steffen Albrecht; Adam Fontebasso; Giuseppe Cinalli; Pasqualino De Antonellis; Massimo Zollo; Michael K Cooper; Reid C Thompson; Simon Bailey; Janet C Lindsey; Concezio Di Rocco; Luca Massimi; Erna M C Michiels; Stephen W Scherer; Joanna J Phillips; Nalin Gupta; Xing Fan; Karin M Muraszko; Rajeev Vibhakar; Charles G Eberhart; Maryam Fouladi; Boleslaw Lach; Shin Jung; Robert J Wechsler-Reya; Michelle Fèvre-Montange; Anne Jouvet; Nada Jabado; Ian F Pollack; William A Weiss; Ji-Yeoun Lee; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Jeffrey R Leonard; Joshua B Rubin; Carmen de Torres; Cinzia Lavarino; Jaume Mora; Yoon-Jae Cho; Uri Tabori; James M Olson; Amar Gajjar; Roger J Packer; Stefan Rutkowski; Scott L Pomeroy; Pim J French; Nanne K Kloosterhof; Johan M Kros; Erwin G Van Meir; Steven C Clifford; Franck Bourdeaut; Olivier Delattre; François F Doz; Cynthia E Hawkins; David Malkin; Wieslawa A Grajkowska; Marta Perek-Polnik; Eric Bouffet; James T Rutka; Stefan M Pfister; Michael D Taylor
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

View more
  41 in total

Review 1.  Genetic and molecular alterations across medulloblastoma subgroups.

Authors:  Patryk Skowron; Vijay Ramaswamy; Michael D Taylor
Journal:  J Mol Med (Berl)       Date:  2015-09-09       Impact factor: 4.599

2.  Medulloblastoma in adults: they're not just big kids.

Authors:  Alvaro Lassaletta; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2016-07       Impact factor: 12.300

3.  Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.

Authors:  Liguo Zhang; Xuelian He; Xuezhao Liu; Feng Zhang; L Frank Huang; Andrew S Potter; Lingli Xu; Wenhao Zhou; Tao Zheng; Zaili Luo; Kalen P Berry; Allison Pribnow; Stephanie M Smith; Christine Fuller; Blaise V Jones; Maryam Fouladi; Rachid Drissi; Zeng-Jie Yang; W Clay Gustafson; Marc Remke; Scott L Pomeroy; Emily J Girard; James M Olson; A Sorana Morrissy; Maria C Vladoiu; Jiao Zhang; Weidong Tian; Mei Xin; Michael D Taylor; S Steven Potter; Martine F Roussel; William A Weiss; Q Richard Lu
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

4.  Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells.

Authors:  Patrícia Benites Gonçalves da Silva; Carolina Oliveira Rodini; Carolini Kaid; Adriana Miti Nakahata; Márcia Cristina Leite Pereira; Hamilton Matushita; Silvia Souza da Costa; Oswaldo Keith Okamoto
Journal:  Cytotechnology       Date:  2015-09-10       Impact factor: 2.058

5.  Functional and neuropsychological late outcomes in posterior fossa tumors in children.

Authors:  Alvaro Lassaletta; Eric Bouffet; Donald Mabbott; Abhaya V Kulkarni
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

Review 6.  p53 and Meduloblastoma.

Authors:  Vijay Ramaswamy; Carolina Nör; Michael D Taylor
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-18       Impact factor: 6.915

7.  Impaired Recent, but Preserved Remote, Autobiographical Memory in Pediatric Brain Tumor Patients.

Authors:  Melanie J Sekeres; Lily Riggs; Alexandra Decker; Cynthia B de Medeiros; Agnes Bacopulos; Jovanka Skocic; Kamila Szulc-Lerch; Eric Bouffet; Brian Levine; Cheryl L Grady; Donald J Mabbott; Sheena A Josselyn; Paul W Frankland
Journal:  J Neurosci       Date:  2018-08-20       Impact factor: 6.167

8.  Surgical outcome of children with medulloblastoma: a retrospective study of a 405-patient series from Children's Cancer Hospital Egypt (CCHE-57357).

Authors:  Abd Elrhman Enayet; Mohamed Nabil; Mohamed Reda Rady; Yasser Yousef; Eman Badawy; Mohamed A El Beltagy
Journal:  Childs Nerv Syst       Date:  2021-02-18       Impact factor: 1.475

9.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

10.  Desmoplastic nodular medulloblastoma in young children: a management dilemma.

Authors:  Mohamed S AbdelBaki; Daniel R Boué; Jonathan L Finlay; Mark W Kieran
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.